---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-009540"
form_type: "8-K"
ticker: "FHTX"
cik: "0001822462"
company_name: "Foghorn Therapeutics Inc."
filed_at: "2024-03-07T23:59:59+00:00"
generated_at: "2026-06-05T01:50:30.827470+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Foghorn Therapeutics 2023 net loss $98.4M, cash $234.1M; FHD-909 IND planned Q2 2024

## Summary
- Net loss $98.4M in 2023 vs $108.9M in 2022; collaboration revenue $34.2M, up from $19.2M.
- Cash $234.1M at Dec 31, 2023; runway into H1 2026.
- FHD-286 AML combo study dose escalation ongoing; first clinical data expected H2 2024.
- Lilly selects FHD-909 (BRM inhibitor) for clinical dev; IND filing Q2 2024 for BRG1-mutated NSCLC.
- Preclinical data for CBP/EP300 degraders at AACR; IND-enabling studies for CBP degrader by end 2024.

## SEC filing metadata
- accession: 0001628280-24-009540
- form_type: 8-K
- ticker: FHTX
- cik: 0001822462
- company_name: Foghorn Therapeutics Inc.
- filed_at: 2024-03-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1822462/000162828024009540/0001628280-24-009540-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1822462/000162828024009540/fhtx-20240307.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-009540
- JSON: https://secwatch.observer/filing/0001628280-24-009540.json
- Plain text: https://secwatch.observer/filing/0001628280-24-009540.txt

## Key facts
- Earnings Releases
  Foghorn Therapeutics Inc. reported the year ended December 31, 2023 results: revenue $34.2 million.
  - Period: the year ended December 31, 2023
  - Revenue: $34.2 million
  - Result: reported results
  source text: three discovery programs using Foghorn’s proprietary Gene Traffic Control platform. Full Year 2023 Financial Highlights • Collaboration Revenues . Collaboration revenues were $34.2 million for the year ended December 31, 2023, compared to $19.2 million for the year ended December 31, 2022. The increase year-over-year was primarily driven by revenue recognized under
  evidence_url: https://www.sec.gov/Archives/edgar/data/1822462/000162828024009540/0001628280-24-009540-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.